Universal Beteiligungs und Servicegesellschaft mbH Invests $631,000 in Organogenesis (NASDAQ:ORGO)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 146,065 shares of Organogenesis, valued at approximately $631,000, during the first quarter, holding around 0.12% of the company.
• Organogenesis stock recently opened at $4.51, down 2.4%, with a twelve-month high of $6.71 and low of $2.28.
• Organogenesis reported a loss of ($0.13) earnings per share for the quarter, missing analysts' expectations, and had revenues of $86.69 million, below estimates of $90.77 million.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Organogenesis (NASDAQ:ORGO - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 146,065 shares of the company's stock, valued at approximately $631,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.12% of Organogenesis at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Merit Financial Group LLC bought a new position in shares of Organogenesis in the 1st quarter valued at about $45,000. Victory Capital Management Inc. bought a new position in shares of Organogenesis in the 1st quarter valued at about $67,000. ProShare Advisors LLC grew its holdings in shares of Organogenesis by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after acquiring an additional 6,689 shares in the last quarter. Algert Global LLC bought a new position in shares of Organogenesis in the 4th quarter valued at about $69,000. Finally, PDT Partners LLC bought a new position in shares of Organogenesis in the 4th quarter valued at about $110,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Organogenesis

In related news, insider Lori Freedman bought 142,379 shares of Organogenesis stock in a transaction dated Thursday, June 5th. The stock was purchased at an average cost of $2.91 per share, with a total value of $414,322.89. Following the transaction, the insider directly owned 837,437 shares of the company's stock, valued at approximately $2,436,941.67. The trade was a 20.48% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have purchased 252,264 shares of company stock worth $725,732. 33.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on ORGO. BTIG Research reissued a "buy" rating on shares of Organogenesis in a report on Tuesday, July 15th. Cantor Fitzgerald reissued an "overweight" rating and set a $7.00 target price on shares of Organogenesis in a report on Tuesday, July 15th.

Organogenesis Stock Down 0.9%

Shares of ORGO stock traded down $0.04 during trading hours on Wednesday, reaching $4.49. The company's stock had a trading volume of 502,169 shares, compared to its average volume of 1,488,607. The firm's 50 day simple moving average is $3.87 and its 200-day simple moving average is $4.04. The company has a market capitalization of $569.18 million, a price-to-earnings ratio of -26.41 and a beta of 1.76. Organogenesis has a fifty-two week low of $2.28 and a fifty-two week high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. The company had revenue of $86.69 million for the quarter, compared to analyst estimates of $90.77 million. Sell-side analysts predict that Organogenesis will post -0.07 earnings per share for the current year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.